The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405

Drug combination studies and their synergy quantification using the Chou-Talalay method

Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739

Clonogenic assay of cells in vitro

Franken, N. A. P., Rodermond, H. M., Stap, J., HAVEMAN, J., & Chris van, B. R. E. E. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,202

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337

FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365

ABC transporters in cancer: more than just drug efflux pumps

Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2789 · Cited by 1,052

Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.

Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 741

Temozolomide and treatment of malignant glioma.

Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · Cited by 722

Temozolomide resistance in glioblastoma multiforme

Lee, S. Y. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.04.007 · Cited by 1,173

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581

Sex differences in cancer mechanisms

Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P. I., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 391

Targeting epigenetic regulators to overcome drug resistance in cancers

Wang, N., Ma, T., & Yu, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01341-7 · Cited by 334

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189

Tumor evolution and chemoresistance in ovarian cancer

Kim, S., Han, Y., Kim, S. I., Kim, H., Kim, S. J., & Song, Y. S. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0063-0 · Cited by 188

Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes

Jezierzański, M. M., Nafalska, N., Stopyra, M., Furgoł, T., Miciak, M., Kabut, J., & Gisterek, I. (2024) · Current Oncology · doi:10.3390/curroncol31070296 · Cited by 192

Genetic alterations in hepatocellular carcinoma: An update

Niu, Z.-S., Niu, X.-J., & Wang, W. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i41.9069 · Cited by 193

Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer

Risom, T., Langer, E. M., Chapman, M. P., Rantala, J., Fields, A. J., Boniface, C., Alvarez, M. J., Kendsersky, N. D., Pelz, C. R., Johnson-Camacho, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05729-w · Cited by 174

Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance

Noch, E., Ramakrishna, R. R., & Magge, R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.04.022 · Cited by 178

MicroRNA in Glioblastoma: An Overview

Banelli, B., Forlani, A., Allemanni, G., Morabito, A., Pistillo, M. P., & Romani, M. (2017) · International Journal of Genomics · doi:10.1155/2017/7639084 · Cited by 171

Selective Inhibition of Lysine‐Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple‐Negative Breast Cancer Therapy

Yang, G., Wang, W., Mok, S. W. F., Chun, W., Law, B. Y. K., Miao, X., Wu, K., Zhong, H., Wong, C., Wong, V. K. W., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807305 · Cited by 163

The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance

Joshi, S. K., Nechiporuk, T., Bottomly, D., Piehowski, P., Reisz, J. A., Pittsenbarger, J., Kaempf, A. J., Gosline, S. J. C., Wang, Y.-T., Hansen, J., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.003 · Cited by 152

Epigenetic Targeting of Glioblastoma

Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 119

The emerging role of KDM5A in human cancer

Yang, G., Zhu, M., Lu, X., Liu, Y., Lu, J., Leung, C., Ma, D., & Chen, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01041-1 · Cited by 116

A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis

Hu, Z., Mi, Y., Qian, H., Guo, N., Yan, A., Zhang, Y., & Gao, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00897 · Cited by 112

Targeting post-translational histone modifying enzymes in glioblastoma

Kunadis, E., Lakiotaki, E., Korkolopoulou, P. A., & Piperi, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107721 · Cited by 113

JMJD family proteins in cancer and inflammation

Wang, M., Jianxin, X., Hong, W., Chen, S., & Huashan, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01145-1 · Cited by 106

Histone lysine demethylases and their functions in cancer

Sterling, J., Menezes, S. V., Abbassi, R. H., & Munoz, L. (2020) · International Journal of Cancer · doi:10.1002/ijc.33375 · Cited by 99

KDM5 demethylases and their role in cancer cell chemoresistance

Plch, J., Hraběta, J., & Eckschlager, T. (2018) · International Journal of Cancer · doi:10.1002/ijc.31881 · Cited by 92

Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance

Gale, M., Sayegh, J., Cao, J. P., Norcia, M., Gareiss, P. C., Hoyer, D., Merkel, J. S., & Yan, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.9539 · Cited by 86

Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model

Alessandrini, F., Menotti, L., Avitabile, E., Appolloni, I., Ceresa, D., Marubbi, D., Campadelli‐Fiume, G., & Malatesta, P. (2019) · Oncogene · doi:10.1038/s41388-019-0737-2 · Cited by 79

Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM 2B

Staberg, M., Rasmussen, R. D., Michaelsen, S. R., Pedersen, H., Jensen, K. E., Villingshøj, M., Skjøth‐Rasmussen, J., Brennum, J., Vitting‐Seerup, K., Poulsen, H. S., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12174 · Cited by 76

Telomerase-Mediated Strategy for Overcoming Non–Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance

Mender, I., LaRanger, R., Luitel, K., Peyton, M., Girard, L., Lai, T., Batten, K. G., Cornelius, C., Dalvi, M. P., Ramirez, M. E., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.06.002 · Cited by 73

Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells

Banelli, B., Daga, A., Forlani, A., Allemanni, G., Marubbi, D., Pistillo, M. P., Profumo, A., & Romani, M. (2017) · Oncotarget · doi:10.18632/oncotarget.16820 · Cited by 73

Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells

Romani, M., Daga, A., Forlani, A., Pistillo, M. P., & Banelli, B. (2019) · Cancers · doi:10.3390/cancers11060878 · Cited by 73

Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells

Corsaro, A., Bajetto, A., Thellung, S., Begani, G., Villa, V., Nizzari, M., Pattarozzi, A., Solari, A., Gatti, M., Pagano, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9575 · Cited by 70

CHOLINE AND NICOTINE INCREASE GLIOBLASTOMA CELL PROLIFERATION BY BINDING AND ACTIVATING α7- AND α9- CONTAINING NICOTINIC RECEPTORS.

Pucci, S., Fasoli, F., Moretti, M., Benfante, R., Lascio, S. D., Viani, P., António, D., Gordon, T. J., Mcintosh, M., Zoli, M., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105336 · Cited by 31

Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation

Parodi, F., Carosio, R., Ragusa, M., Pietro, C. D., Maugeri, M., Barbagallo, D., Sallustio, F., Allemanni, G., Pistillo, M. P., Casciano, I., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.10.006 · Cited by 52

KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance

Feng, T., Wang, Y., Yan, L., & Zhang, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6960 · Cited by 52

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses

Menotti, L., Avitabile, E., Gatta, V., Malatesta, P., Petrovic, B., & Campadelli‐Fiume, G. (2018) · Viruses · doi:10.3390/v10070352 · Cited by 48

Pharmacological inhibition of KDM5A for cancer treatment

Yang, G., Wu, J., Miao, L., Zhu, M., Zhou, Q., Lu, X., Lu, J., Leung, C., Ma, D., & Chen, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113855 · Cited by 46

Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability

Barbieri, F., Würth, R., Pattarozzi, A., Verduci, I., Mazzola, C., Cattaneo, M. G., Tonelli, M., Solari, A., Bajetto, A., Daga, A., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00899 · Cited by 46

Group Behavior and Emergence of Cancer Drug Resistance

Bhattacharya, S., Mohanty, A. R., Achuthan, S., Kotnala, S., Jolly, M. K., Kulkarni, P., & Salgia, R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.009 · Cited by 44

Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells

Angeletti, F., Fossati, G., Pattarozzi, A., Würth, R., Solari, A., Daga, A., Masiello, I., Barbieri, F., Florio, T., & Comincini, S. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00107 · Cited by 45

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase

Poon, W. S., Woo, P. M., Li, Y., Chan, A. Y., Ng, S. P., Loong, H. H.-F., Chan, D. M., & Wong, G. K. C. (2019) · Glioma · doi:10.4103/glioma.glioma_3_19 · Cited by 48

Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis

Yoo, J. H., Kim, G. W., Jeon, Y. H., Kim, J. Y., Lee, S. W., & Kwon, S. H. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00902-0 · Cited by 42

Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma

Maier, J. P., Ravi, V. M., Kueckelhaus, J., Behringer, S. P., Garrelfs, N., Will, P., Sun, N., von Ehr, J., Goeldner, J. M., Pfeifer, D., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03937-9 · Cited by 39

Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?

Ohguchi, Y., & Ohguchi, H. (2022) · Cancers · doi:10.3390/cancers14133270 · Cited by 39

KDM5A Regulates a Translational Program that Controls p53 Protein Expression

Hu, D., Jablonowski, C. M., Cheng, P.-H., AlTahan, A. M., Li, C., Wang, Y., Palmer, L. E., Lan, C., Sun, B., Abu‐Zaid, A., et al. (2018) · iScience · doi:10.1016/j.isci.2018.10.012 · Cited by 34

Improving the Oral Bioavailability of an Anti-Glioma Prodrug CAT3 Using Novel Solid Lipid Nanoparticles Containing Oleic Acid-CAT3 Conjugates

Wang, H., Lin, L., Ye, J., Wang, R., Wang, R., Hu, J., Wang, Y., Dong, W., Xia, X., Yang, Y., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020126 · Cited by 33

α9-Containing Nicotinic Receptors in Cancer

Pucci, S., Zoli, M., Clementi, F., & Gotti, C. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.805123 · Cited by 32

Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas

Pérez‐García, V. M., Ayala-Hernández, L. E., Belmonte-Beitia, J., Schucht, P., Murek, M. K., Raabe, A., & Sepúlveda-Sánchez, J. M. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006778 · Cited by 32

Targeting histone demethylases as a potential cancer therapy (Review)

Diao, W., Zheng, J., Li, Y., Wang, J., & Xu, S. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5393 · Cited by 29

Identification of ryuvidine as a KDM5A inhibitor

Mitsui, E., Yoshida, S., Shinoda, Y., Matsumori, Y., Tsujii, H., Tsuchida, M., Wada, S., Hasegawa, M., Ito, A., Mino, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46346-x · Cited by 32

The function of histone methylation and acetylation regulators in GBM pathophysiology

McCornack, C. R., Woodiwiss, T. R., Hardi, A., Yano, H., & Kim, A. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144184 · Cited by 33

An Update on the Epigenetics of Glioblastomas

Ferreira, W. A. S., Pinheiro, D. D. R., da Costa, C. A., Rodrigues-Antunes, S., Araújo, M. D., Barros, M. B. L., Teixeira, A. C. D. S., Faro, T. A. S., Burbano, R. M. R., de Oliveira, E. H. C., et al. (2016) · Epigenomics · doi:10.2217/epi-2016-0040 · Cited by 29

Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells

Song, X.-H., Yang, L., Zheng, X., Zhu, Q., Liao, X.-L., Liu, K., Zhang, W., Peng, Q., Zhu, Y., Zhao, L.-Y., et al. (2023) · MedComm · doi:10.1002/mco2.342 · Cited by 28

MicroRNAs as Multifaceted Players in Glioblastoma Multiforme

Mercatelli, N., Galardi, S., & Ciafrè, S. A. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.03.002 · Cited by 27

Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy

Mishchenko, T. A., Olajide, O. J., Gorshkova, E. N., Vedunova, M. V., & Krysko, D. V. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.007 · Cited by 26

The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells

Pattarozzi, A., Carra, E., Favoni, R. E., Würth, R., Marubbi, D., Filiberti, R. A., Mutti, L., Florio, T., Barbieri, F., & Daga, A. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0573-7 · Cited by 26

Identification of dysregulated competing endogenous RNA networks in glioblastoma: A way toward improved therapeutic opportunities

Rahnama, S., Bakhshinejad, B., Farzam, F., Bitaraf, A., Ghazimoradi, M. H., & Babashah, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119488 · Cited by 25

Epigenetic regulation of tumor-immune symbiosis in glioma

Liu, Y., Ali, H. A., Khan, F., Pang, L., & Chen, P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.02.004 · Cited by 26

Chemical Inhibitors Targeting the Histone Lysine Demethylase Families with Potential for Drug Discovery

Das, N. D., Niwa, H., & Umehara, T. (2023) · Epigenomes · doi:10.3390/epigenomes7010007 · Cited by 26

The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response

Crake, R., Burgess, E. R., Royds, J. A., Phillips, E., Vissers, M. C. M., & Dachs, G. U. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.619300 · Cited by 25

IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy

Berger, A. J., Gigi, E., Kupershmidt, L., Meir, Z., Gavert, N. S., Zwang, Y., Pri-Or, A., Gilad, S., Harush, U., Haviv, I., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00261-1 · Cited by 22

KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer

Liu, H., Lin, J., Zhou, W., Moses, R., Dai, Z., Kossenkov, A. V., Drapkin, R., Bitler, B. G., Karakashev, S. V., & Zhang, R. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0088 · Cited by 23

8-Hydroxyquinoline-modified ruthenium( ii ) polypyridyl complexes for JMJD inhibition and photodynamic antitumor therapy

Ma, X.-R., Lu, J., Yang, P., Zhang, Z., Huang, B., Li, R., & Ye, R. (2022) · Dalton Transactions · doi:10.1039/d2dt01765b · Cited by 23

Chromatin Regulators as a Guide for Cancer Treatment Choice

Gurard‐Levin, Z. A., Wilson, L. O. W., Pancaldi, V., Postel-Vinay, S. C., Sousa, F. G., Réyès, C., Marangoni, E., Gentien, D., Valencia, A., Pommier, Y. G., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1008 · Cited by 24

High density is a property of slow-cycling and treatment-resistant human glioblastoma cells

Sabelström, H., Quigley, D. A., Fenster, T., Foster, D. J., Fuchshuber, C. A. M., Saxena, S., Yuan, E., Li, N., Paterno, F., Phillips, J. J., et al. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.03.003 · Cited by 23

Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors

Kashani, E., Schnidrig, D., Gheinani, A. H., Ninck, M. S., Zens, P., Maragkou, T., Baumgartner, U., Schucht, P., Rätsch, G., Rubin, M. A., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac220 · Cited by 23

Selective Inhibition of Lysine‐Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple‐Negative Breast Cancer Therapy

Yang, G., Wang, W., Mok, S. W. F., Chun, W., Law, B. Y. K., Miao, X., Wu, K., Zhong, H., Wong, C., Wong, V. K. W., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201807305 · Cited by 21

Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview

McCann, T. S., Sobral, L. M., Self, C., Hsieh, J. C. Y., Sechler, M., & Jedlicka, P. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1580692 · Cited by 21

Histone demethylase KDM5A promotes tumorigenesis of osteosarcoma tumor

Peng, D., Lin, B., Xie, M., Zhang, P., Guo, Q., Li, Q., Gu, Q., Yang, S., & Li, S. (2021) · Cell Death Discovery · doi:10.1038/s41420-020-00396-7 · Cited by 21

Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O-6-Methylguanine-DNA Methyltransferase

Rao, V., Kumar, G., Vibhavari, R. J. A., Nandakumar, K., Thorat, N. D., Chamallamudi, M. R., & Kumar, N. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220404180944 · Cited by 20

Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia

Garcia, T. B., Uluisik, R. C., Linden, A. A. V., Jones, K. L., Venkataraman, S., Vibhakar, R., & Porter, C. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00296 · Cited by 19

Spatial heterogeneity in glioblastoma: Decoding the role of perfusion

Saha, S., Bhat, A., Kukal, S., Phalak, M., & Kumar, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189383 · Cited by 18

Faculty of Bioscience Engineering

Coussement, J. (2014) · Cited by 16

Evidence of a dual mechanism of action underlying the anti-proliferative and cytotoxic effects of ammonium-alkyloxy-stilbene-based α7- and α9-nicotinic ligands on glioblastoma cells

Pucci, S., Bolchi, C., Bavo, F., Pallavicini, M., Palma, C. D., Renzi, M., Fucile, S., Benfante, R., Lascio, S. D., Lattuada, D., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105959 · Cited by 15

The role of histone H3 lysine demethylases in glioblastoma

Young, D. L., Guha, C., & Sidoli, S. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10114-1 · Cited by 13

The epigenome and the many facets of cancer drug tolerance

Moore, P. C., Henderson, K. W., & Classon, M. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.002 · Cited by 14

Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A

Horton, J. R., Liu, X., Wu, L., Zhang, K., Shanks, J. R., Zhang, X., Rai, G., Mott, B. T., Jansen, D. J., Kales, S. C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00261 · Cited by 13

KDM5A regulates the growth and gefitinib drug resistance against human lung adenocarcinoma cells

Wu, H. G., Xu, L., & Hu, X. (2022) · 3 Biotech · doi:10.1007/s13205-021-03018-w · Cited by 12

The Cross Marks the Spot: The Emerging Role of JmjC Domain-Containing Proteins in Myeloid Malignancies

Staehle, H. F., Pahl, H. L., & Jutzi, J. S. (2021) · Biomolecules · doi:10.3390/biom11121911 · Cited by 12

KDM5 family of demethylases promotes CD44-mediated chemoresistance in pancreatic adenocarcinomas

Wang, D., Zhang, Y., Liao, Z., Ge, H., Güngör, C., & Li, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-44536-2 · Cited by 11

Roles of KDM5 demethylases in therapeutic resistance of cancers

Chen, X., Chen, M., Gu, X., Zhou, Q., Zhao, Y., Yang, Y., Zhang, H., & Yang, X. (2025) · Epigenetics & Chromatin · doi:10.1186/s13072-025-00624-3 · Cited by 11

Integrative analysis of rewired central metabolism in temozolomide resistant cells

Immanuel, S. R. C., Ghanate, A. D., Parmar, D. S., Marriage, F., Panchagnula, V., Day, P. J., & Raghunathan, A. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.073 · Cited by 11

The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma

Zhang, X., Li, L., Li, Y., Dong, C., Shi, J., Guo, X., & Sui, A. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149252 · Cited by 11

A novel infram deletion in MSH6 gene in glioma: Conversation on MSH6 mutations in brain tumors

Zayeri, Z. D., Birgani, M. T., Asl, J. M., Kashipazha, D., & Hajjari, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27759 · Cited by 10

Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment

Abballe, L., & Miele, E. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i7.670 · Cited by 11

Transcriptomics-Based Phenotypic Screening Supports Drug Discovery in Human Glioblastoma Cells

Shapovalov, V., Kopanitsa, L., Pruteanu, L.-L., Ladds, G., & Bailey, D. S. (2021) · Cancers · doi:10.3390/cancers13153780 · Cited by 10

The Molecular Basis of Histone Demethylation

Horton, J. R., Gale, M., Yan, Q., & Cheng, X. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_7 · Cited by 10

Potential new targets and drugs related to histone modifications in glioma treatment

Wei, X., Xiao, B., Wang, L., Zang, L., & Che, F. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104942 · Cited by 9

The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article

Azab, M. A. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4040018 · Cited by 9

Different Molecular Mechanisms Mediate Direct or Glia-Dependent Prion Protein Fragment 90–231 Neurotoxic Effects in Cerebellar Granule Neurons

Thellung, S., Gatta, E., Pellistri, F., Villa, V., Corsaro, A., Nizzari, M., Robello, M., & Florio, T. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9749-2 · Cited by 8

KDM5B predicts temozolomide-resistant subclones in glioblastoma

Ullrich, V., Ertmer, S., Baginska, A., Dorsch, M., Gull, H. H., Cima, I., Berger, P., Dobersalske, C., Langer, S., Meyer, L., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108596 · Cited by 8

Drug-tolerant persister cells in acute myeloid leukemia: pressing challenge and promising new strategies for treatment

Li, M., Wang, X., He, W., & Zhou, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1586552 · Cited by 8

Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy

Chiou, J., Impedovo, V., Huynh, Y. B., Gorgoglione, R., Penalva, L. O. F., Lodi, A., Brenner, A. J., & Tiziani, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020474 · Cited by 9

Epigenetic Regulation Towards Acquired Drug Resistance in Cancer

Ketkar, M., & Dutt, S. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-07634-3_14 · Cited by 7

Role of Lysine-specific Demethylase 1 and Its Small Molecule Inhibitors in Glioblastoma Multiforme Therapy

Mitra, R., & Ayyannan, S. R. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220421092414 · Cited by 6

A computer aided drug discovery based discovery of lead‐like compounds against KDM5A for cancers using pharmacophore modeling and high‐throughput virtual screening

Tariq, A., Rehman, H. M., Mateen, R. M., Ali, M., Mutahir, Z., Afzal, M. S., Sajjad, M., Gul, R., & Saleem, M. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26262 · Cited by 6

Key methylation modifications in glioma stem cells

Cai, L., Sun, X., Li, R., Ping, Y., Lv, S., & Chen, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189527 · Cited by 5

Mechanistic QSAR modeling derived virtual screening, drug repurposing, ADMET and in - vitro evaluation to identify anticancer lead as lysine-specific demethylase 5a inhibitor

Jawarkar, R. D., Zaki, M. E. A., Al‐Hussain, S. A., Al‐Mutairi, A. A., Samad, A., Masand, V. H., Humane, V., Mali, S. N., Alzahrani, A. Y. A., Rashid, S., et al. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2319104 · Cited by 5

Application of the antitussive agents oxelaidin and butamirate as anti-glioma agents

Lee, S.-J., Yeom, S.-Y., Lee, J., & Park, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-89238-9 · Cited by 5

Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomasPreprint

Pérez‐García, V. M., Ayala-Hernández, L. E., Belmonte-Beitia, J., Schucht, P., Murek, M. K., Raabe, A., & Sepúlveda-Sánchez, J. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/521559 · Cited by 5

Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations

Mandal, M., Banerjee, I., & Mandal, M. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01859-z · Cited by 6

Time-lapse microscopic observation of non-dividing cells in cultured human osteosarcoma MG-63 cell line

Dosch, J., Hadley, E., Wiese, C., Soderberg, M., Houwman, T., Ding, K., Kharazova, A., Collins, J. L., van Knippenberg, B., Gregory, C. A., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1395535 · Cited by 4

Convergent epigenetic regulation of glial plasticity in myelin repair and brain tumorigenesis: A focus on histone modifying enzymes

Wang, J., & Lu, Q. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105040 · Cited by 5

The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets

Hong, Y., Guo, H., Chen, Q., & Yu, C. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00434-3 · Cited by 3

Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells

Banelli, B., Daga, A., Forlani, A., Allemanni, G., Marubbi, D., Pistillo, M. P., Profumo, A., & Romani, M. (2017) · Oncotarget · doi:10.18632/oncotarget.16820 · Cited by 73

Histone demethylase KDM4C confers temozolomide resistance to glioblastoma cells by epigenetically regulating E2F6

Kim, G. W., Lee, D. H., Yoo, J. H., Jeon, Y. H., Lee, S. W., Oh, S. Y., & Kwon, S. H. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01580-y · Cited by 1

Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells

Romani, M., Daga, A., Forlani, A., Pistillo, M. P., & Banelli, B. (2019) · Cancers · doi:10.3390/cancers11060878 · Cited by 73

DDDR-13. A Brain-Penetrant Epigenetic Strategy to Overcome Therapy-Refractory Glioblastoma

Lo, W., Wu, A.-C., Chen, P., & Chuang, J. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf201.0650

Chemical screens identify HDAC6 as an epigenetic vulnerability in acquired Temozolomide-resistant models of glioblastomaPreprint

Aksu, F., Cevatemre, B., Degirmenci, N. P., Kala, E. Y., Uçku, D., Philpott, M., Cribbs, A. P., Dunford, J. E., Oppermann, U. C. T., Açılan, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723296